Detecting copy number status and uncovering subclonal markers in heterogeneous tumor biopsies

BMC Genomics

Table 1 Characterization of samples by disease status, stage and BRAF or NRAS mutation

Sample_ID	Normal/Nevus/Melanoma	Stage	BRAF status	NRAS status
HFSC	Normal	Normal	NA	NA
Nbmel	Normal	Normal	NA	NA
YULOVY	Melanoma	I, primary	WT	Q61L
YUPLA	Melanoma	II	WT	WT
YUGOE	Melanoma	III	WT	WT
YUKIM	Melanoma	III	WT	Q61R
YUROL	Melanoma	III	WT	WT
YUPAO	Melanoma	III, acral	WT	WT
YUCAS	Melanoma	IV	WT	WT
YUCHER	Melanoma	IV	WT	Q61R
YUMAG	Melanoma	IV	WT	Q61R / WT
YUROB	Melanoma	IV	WT	WT
YUSIV	Melanoma	IV	WT	WT
YUTUR	Melanoma	IV	WT	WT
YUZOR	Melanoma	IV	WT	WT
YUWERA	Melanoma	IV, acral	WT	WT
YUHOIN	Melanoma	IV, primary	WT	WT
YUDOSO	Melanoma	llb, primary	WT	Q61K / WT
YUHEIK	Melanoma	primary	WT	WT
YUFULO	Melanoma	primary	WT	Q61L / WT
YUSTE	Melanoma	III	V600E	WT
YUCAL	Melanoma	IV	V600E	WT
YUSAC	Melanoma	IV	V600E	WT
YUGEN8	Melanoma	IV	V600E	WT
YUCLIR	Giant nevus	Giant nevus	V600E / WT	WT
YUSIK	Melanoma	III+	V600E / WT	WT
YUNIBO	Melanoma	IIb, primary	V600K	WT
YUKSI	Melanoma	IV	V600K	WT
YULAC	Melanoma	IV	V600K	WT
YUMAC	Melanoma	IV	V600K	WT
YURIF	Melanoma	IV	V600K	WT
YUSIT	Melanoma	IV	V600K / WT	WT

Samples have been characterized by disease status, stage and BRAF or NRAS mutation.

ISSN: 1471-2164